Pharma-Bio Serv Inc. logo

Pharma-Bio Serv Inc. (PBSV)

Market Open
12 Aug, 20:00
OTCQB OTCQB
$
0. 60
-0.04
-6.25%
$
18.37M Market Cap
26.67 P/E Ratio
0% Div Yield
0 Volume
0.08 Eps
$ 0.64
Previous Close
Day Range
0.6 0.6
Year Range
0.31 0.67
Want to track PBSV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 27 days
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2024

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2024

DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively, a decrease of approximately $2.2 million and $6.2 million, respectively, when compared to the same periods last year. Net loss for the three and nine months ended July 31, 2024 were approximately $0.3 million and $0.8 million, respectively, compared to the same periods last year to a net income of approximately $0.5 million and $1.4 million, respectively.

Accesswire | 11 months ago
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024

DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and six months ended April 30, 2024 were approximately $2.4 and $4.8, million, respectively, a decrease of approximately $2.2 and $4.0 million when compared to the same periods last year. Net loss for the three and six months ended April 30, 2024 were approximately $0.2 and $0.5 million, respectively, compared to the same periods last year to a net income of approximately $0.4 and $0.8 million, respectively.

Accesswire | 1 year ago